PARP11: A promising drug target and biomarker for the treatment of diseases associated with protein dysfunction

Target Name: PARP11

NCBI ID: G57097

PARP11

PARP11: A promising drug target and biomarker for the treatment of diseases associated with protein dysfunction

Abstract:

Protein mono-ADP-ribosyltransferase PARP11 (isoform a) is a key enzyme in the DNA damage repair pathway. Disruptions in this pathway have been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. PARP11 plays a crucial role in the repair of DNA double-strand breaks, which are a common form of genetic damage caused by exposure to radiation, viruses, or other stressors. In this article, we will discuss the role of PARP11 in disease development and highlight its potential as a drug target and biomarker.

Introduction:

The DNA double-strand break is a critical molecular structure that ensures the stability and integrity of the genetic material. DNA double-strand breaks can occur due to various factors, including damage from radiation, viruses, or other stressors. These breaks can result in the formation of an abnormally stable DNA molecule, which can lead to the development of cancer, neurodegenerative diseases, and autoimmune disorders.

Protein mono-ADP-ribosyltransferase PARP11 (isoform a) is an enzyme involved in the repair of DNA double-strand breaks. PARP11 is a key enzyme in the DNA damage repair pathway, and its dysfunction has been implicated in the development and progression of various diseases.

Role of PARP11 in disease development:

The DNA damage repair pathway is a critical network that ensures the stability and integrity of the genetic material. Disruptions in this pathway have been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

PARP11 plays a crucial role in the repair of DNA double-strand breaks. When DNA double-strand breaks occur, PARP11 is responsible for repairing them. PARP11 uses a unique mechanism of repair, which involves the transfer of an ADP-ribose molecule to the broken DNA strand. This repair mechanism allows PARP11 to specifically repair the most vulnerable double-strand breaks in the DNA.

Disruptions in the DNA damage repair pathway have been linked to the development of various diseases. For example, DNA double-strand breaks can occur during the development of cancer, leading to the formation of abnormally stable DNA molecules. Similarly, disruptions in the DNA damage repair pathways have been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

PARP11 as a drug target:

PARP11 is a potential drug target for the treatment of diseases associated with protein dysfunction. By targeting PARP11, researchers can develop new treatments for diseases that are currently treated with limited success.

One approach to targeting PARP11 is to develop drugs that inhibit the activity of PARP11. These drugs would work by binding to the enzyme and preventing it from functioning. This approach has been used to develop drugs for various diseases, including cancer and neurodegenerative diseases.

Another approach to targeting PARP11 is to develop drugs that modulate its activity. For example, researchers have developed drugs that bind to PARP11 and alter its structure, leading to changes in its activity. These drugs have the potential to be more effective than inhibitors, as they can work at lower concentrations.

PARP11 as a biomarker:

PARP11 is also a potential biomarker for the detection and diagnosis of diseases associated with protein dysfunction. The DNA damage repair pathway is a critical network that ensures the stability and integrity of the genetic material, and disruptions in this pathway have been linked to the development and progression of various diseases.

Therefore, the dysfunction of PARP11 can be used as a biomarker for diseases associated with protein dysfunction. Researchers can use this information to develop new treatments for diseases that are currently treated with limited success.

Conclusion:

In conclusion, PARP11 is an enzyme involved in the repair of DNA double-strand breaks that plays a crucial role in the DNA damage repair pathway. Disruptions in this pathway have been linked to the development and progression of various diseases, including cancer, neurodegenerative diseases , and autoimmune disorders. As a result, PARP11 is a promising drug target and biomarker for the treatment of these diseases.

Protein Name: Poly(ADP-ribose) Polymerase Family Member 11

Functions: Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins (PubMed:25043379, PubMed:25673562). Plays a role in nuclear envelope stability and nuclear remodeling during spermiogenesis (By similarity)

The "PARP11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PARP11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets